<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117662</url>
  </required_header>
  <id_info>
    <org_study_id>200710602</org_study_id>
    <nct_id>NCT01117662</nct_id>
  </id_info>
  <brief_title>Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients</brief_title>
  <acronym>RIACT</acronym>
  <official_title>Efficacy of Rituximab in Acute Cellular Rejection With B-cell Infiltrates in Renal Transplant Patients - Randomized Placebo Controlled Double Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney allograft rejection is the major cause for a loss of graft function and has a
      negative impact on long-term graft survival. Anti-rejection therapy traditionally focuses on
      T cell-mediated mechanisms of renal allograft rejection. However, available agents that
      affect T-cell pathways have only little impact on long-term graft survival. There is
      increasing evidence that B-cells play an important role in acute transplant rejections. CD20+
      B cell infiltrates in acute T-cell mediated rejections are frequent and correlate with a
      worse response to conventional anti-rejection treatment and an increased risk of graft loss.
      In one pilot study, supported by several case reports, a beneficial effect of Rituximab for
      the treatment of acute rejection episodes with intrarenal B-cell infiltrates was shown.
      However, despite the promise of these observations solid evidence is required before
      incorporating this treatment option into a general treatment recommendation.

      In a multicenter randomized placebo controlled double blind phase III trial the investigators
      want to demonstrate that Rituximab in addition to standard treatment with steroid-boli is
      superior to the standard treatment alone regarding long-term kidney function. If the proposed
      study proves that Rituximab treatment of acute rejections is beneficial for the long-term
      allograft function, the conventional rejection therapy needs to be revised to this novel
      concept of B- cell targeting
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The planned recruitment number of 180 Patient could not been achieved.
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 23, 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the GFR (glomerular filtration rate) one year after intervention compared to the baseline GFR before the rejection, which is calculated by a defined algorithm</measure>
    <time_frame>Baseline, 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of interstitial fibrosis and tubular atrophy between the biopsy that led to enrolment in the study and a scheduled protocol biopsy one year after intervention (&quot;∆IFTA-Score&quot;)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Acute Rejection</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous application of placebo (NaCl 0,9 %) matching active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous application of placebo (NaCl 0,9 %) matching active treatment</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. male or female patients age ≥ 18 at the time of the inclusion in the study

          2. male or female patients after kidney transplantation if medically justifiable (cave:
             previous immunosuppression, particularly prior induction therapies or biologicals).

          3. Proof of an acute rejection in kidney transplant according to Banff-criteria:
             T-cell-mediated rejection as borderline, grade IA/B, IIA/B (no v-only), if one or more
             results are available as significant B-cell infiltrates CD20≥20 / high power field,
             glomerulitis, peritubular capillaritis or C4d positivity (with the exception of
             ABO-incompatible transplantations) as well as patients who have no T-cell-mediated
             acute rejection, but signs of acute humoral rejection (as listed above according to
             the criteria glomerulitis, peritubular capillaritis, C4d positivity) who have to be
             treated according to medical opinion of the physician with steroid therapy. The
             evidence of rejection can be performed by a protocol or indication biopsy.

          4. SV40-negativity in the biopsy

          5. GFR calculated using the MDRD-Formula &gt; 25 ml/min/1,73 m² in the time period before
             the noticed rejection.

          6. Presence of a negative pregnancy test and consent to a highly effective contraceptive
             method (i.e. failure rate less than 1% per year, which are implants, injectable
             contraceptives, combined oral contraceptives, intrauterine devices (only hormone
             spirals), sexual abstinence or vasectomy of the partner) in patients of child-bearing
             age. This is not required when bilateral sterilization or ovariectomy of the patient
             and in patients that have exclusively female sex partners. Presence of consent to a
             highly effective contraceptive method for male patient.

          7. Informed consent

        Exclusion criteria:

          1. Known contraindications, resp. incompatibility for Rituximab and/or for the
             concomitant medication

          2. Administration of Rituximab within the last 12 months before inclusion

          3. Simultaneous participation in an other clinical study or participation in an other
             clinical study within the last 30 days

          4. Breastfeeding women or pregnant women

          5. Persons who fail to assess essence, meaning and significance of the clinical study and
             act along these lines (according to § 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG)

          6. Existence of an active CMV-infection, existence of a HIV-infection, existence of a
             replicative hepatitis B or C, existence of other grave infections

          7. Cardiac insufficiency in phase NYHA III-IV

          8. High grade cardiac arrhythmias

          9. Unstable coronary heart disease

         10. Poorly adjusted diabetes mellitus (HbA1c &gt; 10 %) at the time of the inclusion in the
             study.

         11. State after splenectomy

         12. Contra-indication referring to a renewed transplant biopsy (e.g. coagulopathy,
             anticoagulation)

         13. Other exclusion criteria according to the estimate of the attending doctor (e.g.
             aggravation of the general health condition, occurrence of a malignant disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen Medizinische Klinik II</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf Klinik für Nephrologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen Nephrologie und Hypertensiologie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Klinik für Nephrologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Medzinische Klinik IV Nephrologie Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologisches Zentrum Niedersachsen 34346 Hannoversch Münden</name>
      <address>
        <city>Hannoversch Münden</city>
        <zip>34346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena Klinik für Innere Medizin III</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel Klinik für Nieren- und Hochdruckkrankheiten Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln Medizinische Klinik IV Nephrologie</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH Medizinische Klinik I</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I der Ludwig-Maximilians-Uniklinik München Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Innere Medizin / Nephrologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Hannover Medical School</investigator_full_name>
    <investigator_title>Hannover Medical School</investigator_title>
  </responsible_party>
  <keyword>transplantation</keyword>
  <keyword>acute rejection</keyword>
  <keyword>kidney</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

